论文部分内容阅读
目的评价芳香化酶抑制剂(来曲唑)和促性腺激素释放激素激动剂(GnRH-α)治疗子宫肌瘤的有效性和安全性。方法采用随机、双盲对照的方法将130例子宫肌瘤患者分为两组。A组:给予来曲唑片2.5 mg,每日1次口服,疗程为12周;B组:给予GnRH-α3.75 mg,每4周1次皮下注射,疗程为12周。用药前和用药4周、8周、12周前一日分别行阴道B超检查及血清血检查,比较子宫及肌瘤体积、卵巢功能情况。结果肌瘤的体积在两组分别下降了50.6%及50.2%,与治疗前相比均有显著意义。A组未出现有意义的血清学改变,B组在治疗4周后出现了有统计学意义的激素水平的下降。结论来曲唑和GnRH-α治疗子宫肌瘤都有确切的临床疗效,来曲唑更大的优势在于不影响激素水平。
Objective To evaluate the efficacy and safety of aromatase inhibitors (letrozole) and gonadotropin-releasing hormone agonists (GnRH-α) in the treatment of uterine fibroids. Methods 130 patients with uterine fibroids were divided into two groups by randomized, double-blind control. Group A: 2.5 mg lelaconazole tablets were given orally once daily for 12 weeks. Group B: GnRH-α 3.75 mg was given subcutaneously once every 4 weeks for 12 weeks. Before treatment and medication 4 weeks, 8 weeks, 12 days before the day of vaginal ultrasound B and serum examination, comparison of uterine and fibroid volume, ovarian function. Results The volume of fibroids decreased by 50.6% and 50.2% in both groups, which was significant compared with that before treatment. No significant serological changes occurred in group A, and a statistically significant decrease in hormone levels occurred in group B after 4 weeks of treatment. Conclusion Letrozole and GnRH-α treatment of uterine fibroids have the exact clinical efficacy, letrozole greater advantage does not affect hormone levels.